"Medication non-compliance is a major risk factor for stroke and heart disease, and we know that non-compliance with stroke prevention medications increases over the year or two after a stroke," said Cheryl D. Bushnell, M.D., M.H.S., director of the Wake Forest Baptist Stroke Center and lead author on the study.
"This study revealed that the majority of patients are compliant in taking their medications, but it also showed us specific vulnerabilities from the patient's perspective that might explain why some patients stop medications. We found that there's a large opening for us to focus efforts towards even better compliance. Specifically, we as providers need to continue educating patients over the long term and not just the first time a medication is started."
Although the risk of a second stroke is highest within the first three months after an initial stroke, the risk is about eight percent in the first year, and five percent per year after that, according to the study. So taking secondary prevention medications long term is critical for preventing a second stroke, which is likely to be even more devastating than the first, Bushnell added.
Nearly 700,000 people in the United States have ischemic strokes each year, and about 160,000 of these events are recurrent,* according to the study, published online this week by the journal Neurology. It is scheduled to appear in the September 20 print issue.
The Adherence eValuation After Ischemic stroke-Longitudinal (AVAIL) Registry aims to collect data on long-term use of secondary prevention medications for one year following stroke, assessing compliance issues from the patients' perspective, as well as system and provider issues, such as what type of doctor the patients saw, what kind of follow up care they had and the patients' understanding of their medications and why they were taking them.
The researchers first studied 2,598 patients from the AVAIL Registry to evaluate how many stroke patients were still taking their secondary prevention medications three months after being discharged from the hospital.
The three-month data appeared in the December 2010 issue of Archives of Neurology, and revealed that about 75 percent of those studied had continued with their full regimen of medications – usually including an aspirin or other type of blood thinner, blood pressure medication and cholesterol lowering medication – three months after discharge.
The one-year data evaluated "persistence," defined as continuation of all secondary stroke prevention medications prescribed at hospital discharge, and "adherence," defined as continuation of all prescribed medications except those stopped according to healthcare provider instructions, to get a true read on whether patients no longer on their medications are discontinuing on their own, or if they are being told by their doctors to stop their secondary prevention regimen.
Of the 2,457 patients who completed one-year interviews, 65.9 percent were "persistent" with their secondary prevention regimen, meaning they were still taking all of the medicines prescribed to them at hospital discharge. Even more patients – 86.6 percent – were "adherent," following doctor's orders and taking all of their medications except those they had been told to discontinue by their healthcare providers.
Although up to one third of stroke patients were no longer taking one or more of their secondary prevention medications within one year of hospital discharge, most did not stop taking the medications on their own, the study authors noted. "Self-discontinuation of these medications is uncommon."
For the nearly 14 percent of patients who did stop taking their secondary prevention medications on their own, this analysis gave investigators important insight into the reasons why patients self-discontinue.
The researchers learned that several key factors affect "non-adherence," or self-discontinuation. These include whether or not a person has health insurance and can afford their medications, whether the patient receives detailed instructions upon discharge about their medications and understands what the medications do and why taking them is important, whether or not the patient is married to a spouse who can help them remember and motivate them to take their medications, and whether the patient is discharged to his or her home or some other location such as a nursing home or in-patient rehabilitation. These findings represent opportunities for providers and support systems to intervene with the goal of improving medication adherence, Bushnell said.
As a result, Bushnell and colleagues at Wake Forest Baptist are implementing a transition coaching program, which will focus on educating stroke patients about their medications before they are discharged and directly following up with them after discharge to remind them about their doctor's appointments, make recommendations on ways to remember taking their medicine (such as using a daily pill box), answer questions about their condition, treatment and medication, and evaluate them a few weeks after discharge for their risk of rehospitalization.
The factors associated with discontinuing medications reflect the challenges many stroke patients face, Bushnell said. "Not only are many patients disabled and unable to work, but the disability from the stroke also affects medication-taking behavior. Streamlining medication regimens, emphasizing appointment-keeping, helping with insurance applications and referring to community support services are all essential to aid in this difficult transition."
Proper education about medications is also extremely important. "Where providers and pharmacists can make a difference with long-term compliance is by reiterating why medications are taken and what the side effects are," she added. "We have incorporated these challenges into our transition coaching program, where our goal is to increase stroke prevention adherence, improve outcomes, and keep people free of a second stroke."
This study was conceived and designed by the AVAIL team, researchers at Duke Clinical Research Institute, the project executive committee and an American Heart Association representative. The AVAIL analyses were also supported in part by a grant from the Agency for Healthcare Research and Quality.
*Numbers according to the 2010 Heart/Stroke Statistics, published annually by the American Heart Association. The numbers have since been updated to 795,000 people in the United States having ischemic strokes, 189,000 of which are recurrent, according to the 2011 Heart/Stroke Statistics.
Media Relations Contacts: Jessica Guenzel, firstname.lastname@example.org, (336) 716-3487; or Bonnie Davis, email@example.com, (336) 716-4977.
Wake Forest Baptist Medical Center (www.wakehealth.edu) is a fully integrated academic medical center located in Winston-Salem, N.C. Wake Forest School of Medicine directs the education and research components, with the medical school ranked among the nation's best and recognized as a leading research center in regenerative medicine, cancer, the neurosciences, aging, addiction and public health sciences. Piedmont Triad Research Park, a division of Wake Forest Baptist, fosters biotechnology innovation in an urban park community. Wake Forest Baptist Health, the clinical enterprise, includes a flagship tertiary care hospital for adults, Brenner Children's Hospital, a network of affiliated community-based hospitals, physician practices and outpatient services. The institution's clinical programs and the medical school are consistently recognized as among the best in the country by U.S.News & World Report.
Jessica Guenzel | EurekAlert!
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction